Effects of aspirin (325 mg/day) on serum high-sensitivity C-reactive protein, cytokines, and adhesion molecules in healthy volunteers

• Published in: The American journal of cardiology Vol. 92; no. 2; pp. 236 - 239
• Main Authors: Azar, Rabih R., Klayme, Samira, Germanos, Mirna, Kassab, Roland, Tawm, Samer, Aboujaoudé, Simon, Naman, Roger
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 15.07.2003; Elsevier; Elsevier Limited
• Subjects: Adult; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Anti-Inflammatory Agents, Non-Steroidal - pharmacology; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Aspirin; Aspirin - administration & dosage; Aspirin - pharmacology; Aspirin - therapeutic use; Biological and medical sciences; Blood. Blood coagulation. Reticuloendothelial system; C-Reactive Protein - analysis; C-Reactive Protein - drug effects; Cell Adhesion Molecules - blood; Cell Adhesion Molecules - drug effects; Coronary Artery Disease - blood; Coronary Artery Disease - prevention & control; Cross-Over Studies; Dose-Response Relationship, Drug; Effects; Female; Health; Humans; Interleukin-6 - blood; Macrophage-1 Antigen - blood; Macrophage-1 Antigen - drug effects; Male; Medical sciences; Middle Aged; Molecules; Pharmacology. Drug treatments; Prospective Studies; Proteins; Reference Values; Human; Intercellular adhesion molecule 1; Low dose; Cytokine; Biological marker; Exploration; Inflammation; Acetylsalicylic acid; Interleukin 6; High sensitivity; Adhesin; Mechanism of action; C reactive protein

This is a randomized, prospective, crossover study designed to test whether aspirin (325 mg/day) possesses any significant anti-inflammatory effect. Levels of-high sensitivity Greactive protein, interleukin-6, soluble intracellular adhesion molecules, and CDllb/CD18 expression on monoctyes were meas...